肝硬化门静脉血栓分类及形成机制研究进展*

doi:10.3969/j.issn.1672-5069.2025.02.001

Abstract

Cui Yeqi, Zhang Shibin. Classification and formation mechanism of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2025, 28(2): 161-164.

[1] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology, 2015, 61(2): 660-7.
[2] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol, 2013, 108(4): 568-574.
[3] Stieber AC, Zetti G, Todo S, et al. The spectrum of portal vein thrombosis in liver transplantation. Ann Surg, 1991, 213(3): 199-206.
[4] Nonami T, Yokoyama I, Iwatsuki S, et al. The incidence of portal vein thrombosis at liver transplantation. Hepatology, 1992, 16(5): 1195-1198.
[5] Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res, 1996, 60(2): 333-338.
[6] Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation, 2000, 69(9): 1873-1881.
[7] Jamieson NV. Changing perspectives in portal vein thrombosis and liver transplantation. Transplantation, 2000, 69(9): 1772-1774.
[8] Bauer J, Johnson S, Durham J, et al. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl, 2006, 12(10): 1544-1551.
[9] Ma J, Yan Z, Luo J, et al. Rational classification of portal vein thrombosis and its clinical significance. PLoS One, 2014, 9(11): e112501.
[10] De Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3): 743-752.
[11] Sarin SK, Philips CA, Kamath PS, et al. Toward a Comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology, 2016, 151(4): 574-577,e3.
[12] 任书瑶, 张博静, 韩国宏. 门静脉高压 Baveno Ⅵ共识:门静脉高压的危险分层及个体化治疗. 中华消化杂志, 2015, 35: 5.
[13] 孙鑫, 刘成海. 肝硬化门静脉高压诊治Baveno Ⅶ共识解读——内科视角. 中国中西医结合消化杂志, 2023, 31: 79-84.
[14] 张国, 王文娟. 《肝硬化门静脉血栓管理专家共识》解读. 中国临床新医学, 2021, 14: 740-744.
[15] Anton A, Campreciós G, Pérez-Campuzano V, et al. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow's triad. J Clin Med, 2022, 11(3): 800.
[16] Saad WE. Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin Intervent Radiol, 2014, 31(3): 262-265.
[17] Odriozola A, Puente Á, Cuadrado A, et al. Portal vein thrombosis in the setting of cirrhosis: A comprehensive review. J Clin Med, 2022, 11(21): 6435.
[18] Sacchetti S, Puricelli C, Mennuni M, et al. Research into new molecular mechanisms in thrombotic diseases paves the way for innovative therapeutic approaches. Int J Mol Sci, 2024, 25(5): 2523.
[19] Driever EG, Von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology, 2022, 75(4): 898-911.
[20] Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood, 2010, 116(6): 878-885.
[21] Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: From primary hemostasis to fibrinolysis. Hepatology, 2020, 71(6): 2135-2148.
[22] Turco L, De Raucourt E, Valla DC, et al. Anticoagulation in the cirrhotic patient. JHEP Rep, 2019, 1(3): 227-239.
[23] 薛春燕, 饶晨怡, 吴玲, 等. 肝硬化静脉曲张出血患者门静脉血栓的临床特征. 中国临床医学, 2023, 30: 454-459.
[24] Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol, 2022, 76(5): 1090-1099.
[25] Giuli L, Pallozzi M, Venturini G, et al. Molecular mechanisms underlying vascular liver diseases: Focus on thrombosis. Int J Mol Sci, 2023, 24(16): 12754.
[26] Ventura P, Venturelli G, Marcacci M, et al. Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. Thromb Res, 2016, 141: 189-195.
[27] Senzolo M, T MS, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int, 2012, 32(6): 919-927.
[28] Cagin YF, Bilgic Y, Berber İ, et al. The risk factors of portal vein thrombosis in patients with liver cirrhosis. Exp Ther Med, 2019, 17(4): 3189-3194.
[29] Tremblay D, Naymagon L, Troy K, et al. The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. Blood Coagul Fibrinolysis, 2020, 31(3): 213-218.
[30] Fortea JI, Carrera IG, Puente Á, et al. Portal thrombosis in cirrhosis: Role of thrombophilic disorders. J Clin Med, 2020, 9(9): 2822.
[31] Gaballa D, Bezinover D, Kadry Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: The portal vein thrombosis risk index. Liver Transpl, 2019, 25(12): 1747-1755.
[32] Von Köckritz L, De Gottardi A, Trebicka J, et al. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep (Oxf), 2017, 5(2): 148-156.
[33] Yan Y, Xiong Z, Wang X, et al. A novel potential mechanism for the development of portal vein thrombosis in cirrhosis based on portal hemodynamics. Insights Imaging, 2022, 13(1): 192.
[34] Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446.
[35] Dai CY, Chuang WL, Yu ML. Predicting portal thrombosis in cirrhosis: Some issues. J Hepatol, 2022, 76(1): 224-225.
[36] Li J, Wang Q, Yang M, et al. Metabolic Disorders and risk of portal vein thrombosis in liver cirrhosis: A systematic review and Meta-analysis. Turk J Gastroenterol, 2022, 33(7): 541-553.
[37] Lopez-Gomez M, Llop E, Puente A, et al. Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. Hepatol Res, 2021, 51(10): 1064-1072.
[38] Ohlendorf J, Kiene H, Wiegandt J, et al. The impact of thrombophilic factors on disease progression in children with biliary atresia-A single-centre cohort study. J Clin Med, 2023, 12(6): 2108.
[39] Quan X, Ye X, Qian S, et al. Portal vein thrombosis associates with high platelet-fibrin clot strength and platelet activation in decompensated cirrhosis: A retrospective study. Dig Liver Dis, 2023, 55(5): 629-636.
[40] Violi F, Pignatelli P, Castellani V, et al. Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis. Blood Rev, 2023, 57: 100998.
[41] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost, 2020, 46(6): 673-681.
[42] Wang L, Guo X, Shao X, et al. Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case-control study. Therap Adv Gastroenterol, 2022, 15: 17562848221087536.
[43] Wang L, Guo X, Xu X, et al. Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2021, 32(2): 125-131.
[44] Politoske D, Ralls P, Korula J. Portal vein thrombosis following endoscopic variceal sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Dig Dis Sci, 1996, 41(1): 185-190.

Classification and formation mechanism of portal vein thrombosis in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lyu Tianfu, Nan Qiong. Anticoagulant therapy in patients with cirrhotic portal hypertension after transjugular intrahepatic porto-systemic shunt [J]. Journal of Practical Hepatology, 2025, 28(2): 165-168.
[2]	He Xiaofei, Chen Jie, Zhao Bin, et al. A comparative study of selective decongestive devascularization of gastrosplenic region and splenectomy and pericardial devascularization combination in the treatment of patients with cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2025, 28(2): 238-241.
[3]	Shi Qian, Li Li, Ni Haotian. Clinical efficacy of tenofovir and Anluo Huaxian capsule combination in the treatment of patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(2): 242-245.
[4]	Liu Chenghuan, Liu Gang, Gan Zhengning, et al. Splenic Gamna-Gandy vesicles by FRFSE sequence of MRI in predicting esophageal and gastric varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(2): 246-249.
[5]	Tian Ruiyuan, Wei Chao, Li Yong. Effect of Yiqi Huoxue Tongluo compound intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(1): 24-27.
[6]	Guo Zhen, Wang Xin, Niu Panxia. Factors influencing the occurrence of hepatitis B viral reactivation and drug-induced liver injury during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis [J]. Journal of Practical Hepatology, 2025, 28(1): 68-71.
[7]	Liu Fei, Yao Jie, Zhang Liqian, et al. Clinical feature and risk factors of sepsis-related liver injury: An analysis of 32 cases [J]. Journal of Practical Hepatology, 2025, 28(1): 76-79.
[8]	Sun Min, Zhang Qian, Xu Gang, et al. Prevalence and risk factors of pulmonary infection in patients with acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2025, 28(1): 84-87.
[9]	Shen Lili, Zhao Lin, Shi Lei. Prevalence of third-generation cephalosporin resistance in patients with decompensated hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2025, 28(1): 88-91.
[10]	Yang Huiling, Zhao Wenzhe, Yang Liuqing, et al. DCE-MRI functional imaging parameters in the diagnosis of decompensated liver functions in patients with hepatitis B-related liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 92-95.
[11]	Ye Peng, Yang Benchang, Mao Ming. Long-term observation of entecavir treatment for histological improvement in patients with compensated hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 96-99.
[12]	Si Tong, Zhu Jiabao, Wu Binbin. Ultrasonography and shear wave elastography in predicting high risk esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 100-103.
[13]	Zhu Ruinong, Song Liqun, Qian Ji. Endoscopic tissue gel injection and endoscopic variceal ligation in treatment of cirrhotics with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(1): 104-107.
[14]	Zhuo Yuhong, Chen Pinghu, Chen Hongcheng, et al. Oral maintaining treatment of propranolol after endoscopic variceal ligation and somatostatin combination for emergent hemostasis in patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(1): 108-111.
[15]	Wang Xuli, Cai Mingyue, Zhou Zhiming, et al. CT-measured liver volume in patients with hepatitis B-induced liver cirrhosis with different Child-Pugh class [J]. Journal of Practical Hepatology, 2025, 28(1): 112-115.